News

January 2018. The Company received approval from Health Canada to begin a Phase 2a study with their lead drug candidate- RPh201- in patients with moderate Alzheimer’s related dementia.

28/01/18

The Company reported that they received approval from Health Canada to begin a 45-80 patient Phase 2a study with their lead drug candidate- RPh201- in patients with moderate Alzheimer’s related dementia. Patients in this multicenter, double blinded, placebo-controlled, study, will be randomized 2:1 (drug to placebo) and will receive twice-weekly subcutaneous injections over a 6-month period. The study will measure cognitive changes from baseline to 6 months between the two groups to see if there is an efficacy trend. The study will take place in at least 4 centers in Ontario and Quebec and final readout is expected Q1 2019.